Clinical Trial Update: The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in Interstitial Lung Disease. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating inhaled nitric oxide for dyspnea and exercise tolerance in interstitial lung disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease

Drugs mentioned

• Inhaled nitric oxide (nitric oxide)

Snippet

Sponsor: University of Alberta | Conditions: Dyspnea | Phase 1, Phase 2 | Status: WITHDRAWN